JP2023510866A - 抗ｇａｌ３抗体および使用方法 - Google Patents

抗ｇａｌ３抗体および使用方法 Download PDF

Info

Publication number
JP2023510866A
JP2023510866A JP2022542784A JP2022542784A JP2023510866A JP 2023510866 A JP2023510866 A JP 2023510866A JP 2022542784 A JP2022542784 A JP 2022542784A JP 2022542784 A JP2022542784 A JP 2022542784A JP 2023510866 A JP2023510866 A JP 2023510866A
Authority
JP
Japan
Prior art keywords
seq
cdr3
cdr2
cdr1
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510866A5 (https=
Inventor
サン，ドンフ
ラソール，スハイル
エー． ゴードン，キャサリン
ホン，ケ
チェン，ファン
マチルダ ボリン，サラ
シチョルス，クセニヤ
ユ，ヤドン
ツァイ，ツンファン
エー．エフ． ウィリアムス，サムエル
ララ，カラン
ウ，ヘン
ワン，ヤン
Original Assignee
トゥルーバインディング，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥルーバインディング，インコーポレイテッド filed Critical トゥルーバインディング，インコーポレイテッド
Publication of JP2023510866A publication Critical patent/JP2023510866A/ja
Publication of JP2023510866A5 publication Critical patent/JP2023510866A5/ja
Priority to JP2025122880A priority Critical patent/JP2025163070A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JP2022542784A 2020-01-13 2021-01-12 抗ｇａｌ３抗体および使用方法 Pending JP2023510866A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025122880A JP2025163070A (ja) 2020-01-13 2025-07-22 抗ｇａｌ３抗体および使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062960300P 2020-01-13 2020-01-13
US62/960,300 2020-01-13
US202063024327P 2020-05-13 2020-05-13
US63/024,327 2020-05-13
US202063092069P 2020-10-15 2020-10-15
US63/092,069 2020-10-15
US202063122409P 2020-12-07 2020-12-07
US63/122,409 2020-12-07
PCT/US2021/013136 WO2021146218A1 (en) 2020-01-13 2021-01-12 Anti-gal3 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025122880A Division JP2025163070A (ja) 2020-01-13 2025-07-22 抗ｇａｌ３抗体および使用方法

Publications (2)

Publication Number Publication Date
JP2023510866A true JP2023510866A (ja) 2023-03-15
JP2023510866A5 JP2023510866A5 (https=) 2024-01-22

Family

ID=76864188

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542784A Pending JP2023510866A (ja) 2020-01-13 2021-01-12 抗ｇａｌ３抗体および使用方法
JP2025122880A Pending JP2025163070A (ja) 2020-01-13 2025-07-22 抗ｇａｌ３抗体および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025122880A Pending JP2025163070A (ja) 2020-01-13 2025-07-22 抗ｇａｌ３抗体および使用方法

Country Status (11)

Country Link
US (2) US20230036181A1 (https=)
EP (1) EP4090685A4 (https=)
JP (2) JP2023510866A (https=)
KR (1) KR20220129030A (https=)
CN (2) CN119930824A (https=)
AU (1) AU2021207461A1 (https=)
BR (1) BR112022013892A2 (https=)
CA (1) CA3166552A1 (https=)
IL (1) IL294486A (https=)
MX (1) MX2022008450A (https=)
WO (1) WO2021146218A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523333A (ja) * 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP7835441B2 (ja) * 2019-12-06 2026-03-25 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024526764A (ja) * 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
CN118524852A (zh) * 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
WO2024073511A2 (en) * 2022-09-28 2024-04-04 Truebinding, Inc. Therapies with anti-gal3 antibodies
WO2025185724A1 (en) * 2024-03-08 2025-09-12 Sunmed Therapeutic Limited Anti-galectin 3 antibodies and their use in epilepsy and related diseases
CN118286392A (zh) * 2024-03-28 2024-07-05 广州医科大学附属妇女儿童医疗中心 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用
WO2025240949A1 (en) * 2024-05-17 2025-11-20 The Administrators Of The Tulane Educational Fund Compositions and methods for the treatment of idiopathic pulmonary fibrosis
WO2025264872A1 (en) * 2024-06-21 2025-12-26 Truebinding, Inc. Methods and compositions for treating neurodevelopmental disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) * 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4792390B2 (ja) * 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UA104132C2 (en) * 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
US8349579B2 (en) * 2007-12-13 2013-01-08 Wayne State University Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
CA2818173C (en) * 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
BR112016013876B1 (pt) * 2013-12-27 2022-03-22 Eliaz Therapeutics, Inc. Dispositivo para realização de plasmaferese
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
AU2019215202B2 (en) * 2018-02-01 2025-11-13 Memorial Sloan Kettering Cancer Center Antibodies to Galectin-3 and methods of use thereof
EP3759145A4 (en) * 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
WO2020160156A2 (en) * 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) * 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523333A (ja) * 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用

Also Published As

Publication number Publication date
MX2022008450A (es) 2022-12-13
CA3166552A1 (en) 2021-07-22
CN115427449A (zh) 2022-12-02
EP4090685A1 (en) 2022-11-23
EP4090685A4 (en) 2024-12-18
BR112022013892A2 (pt) 2022-10-04
US20250145722A1 (en) 2025-05-08
US20230036181A1 (en) 2023-02-02
IL294486A (en) 2022-09-01
KR20220129030A (ko) 2022-09-22
CN119930824A (zh) 2025-05-06
JP2025163070A (ja) 2025-10-28
WO2021146218A1 (en) 2021-07-22
AU2021207461A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20250145722A1 (en) Anti-gal3 antibodies and methods of use
US20250243282A1 (en) Methods of treating inflammatory diseases by blocking galectin-3
US20210380680A1 (en) Anti-claudin antibodies and uses thereof
JP7803577B2 (ja) 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート
US20250026838A1 (en) Methods of preventing protein aggregation
US20240158512A1 (en) Anti-gal3 antibody formulations and methods of use thereof
US20220411514A1 (en) Anti-gal3 antibodies and methods of use for insulin resistance
US20230279120A1 (en) Methods of treating or inhibiting cardiovascular diseases
JP7835441B2 (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
HK40125857A (zh) 抗gal3抗体和使用方法
HK40078860A (en) Anti-gal3 antibodies and methods of use
TW202543672A (zh) 抗gpc1抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217